ZHANGSHU, China, Oct. 23, 2025 /PRNewswire/ -- A report from Jiangxi International Communication Center (JXICC): "Without Zhangshu, medicines are incomplete; without Zhangshu, medicines lack efficacy.
China Pharmaceutical University has prepared and tested sphingomyelin phosphodiesterase (SMPD1; aSMase) inhibitors potentially useful for the treatment of cancer, autoimmune disease, chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results